Metformin Vicious Cycle

Skeletal muscle is responsible for roughly 80% of the work your body does to clear sugar out of your blood after a meal, and that number comes from direct measurement of glucose uptake across tissues, not an estimate. When you eat something and your blood sugar rises, your pancreas releases insulin, insulin signals your muscle cells to pull that glucose in and use it, and the blood sugar comes back down. That is the whole system working correctly.

When you do not have enough muscle, or when the muscle you have stops responding to insulin properly, that clearing process slows down and blood sugar stays elevated longer than it should. This is what researchers mean when they talk about skeletal muscle as the primary site of insulin-mediated glucose disposal. It is not just one piece of the puzzle. It is most of the puzzle.

So what happens when you develop insulin resistance? Your doctor prescribes something to help manage blood sugar. And the most common first prescription for type 2 diabetes is metformin.

Here is what that drug actually does inside your cells.

Your mitochondria produce energy through a series of steps, and the first of those steps involves a protein complex called Complex I, which is essentially the opening gate in the mitochondrial energy production chain. Metformin inhibits Complex I, which means it partially restricts the normal flow of energy production inside the mitochondria. When that happens, the cell senses an energy shortage and activates an enzyme called AMPK, which stands for AMP-activated protein kinase and functions like a cellular low-fuel alarm. When AMPK turns on, the cell starts trying to bring in more glucose from the bloodstream to compensate.

That is why the drug works. AMPK activation does improve glucose uptake into muscle tissue, and blood sugar numbers come down. The mechanism is real and the effect is real.

But AMPK does more than one thing, and this is where the problem begins.

AMPK also suppresses a pathway called mTOR, specifically a complex called mTORC1, which is the signaling pathway your body uses to build new muscle protein after a training stimulus. When you lift weights, you damage muscle fibers in a controlled way, and mTOR responds to that stimulus by activating the machinery for muscle protein synthesis. That is how muscle grows. AMPK does this through two separate mechanisms: it phosphorylates a protein called TSC2 which puts a brake on mTOR directly, and it also phosphorylates a protein called Raptor which suppresses mTORC1 activity through a second independent route. Both pathways lead to the same outcome. The signal to build muscle gets turned down.

Think of it like a gas pedal and a brake. Resistance training puts its foot on the gas for muscle growth. Metformin applies the brake through AMPK at the same time, and the net result is less forward movement than you would get without the drug in the system.

This was tested directly in a randomized controlled trial called the MASTERS trial, which enrolled 94 adults over the age of 65 and put them all through 14 weeks of progressive resistance training. Half took metformin, half took a placebo. The researchers actually expected metformin to enhance the training response because of its known anti-inflammatory properties, and inflammation is one of the things that blunts muscle adaptation in older adults. The hypothesis was reasonable. The result went the other direction. The placebo group gained significantly more muscle mass and more muscle density than the metformin group by the end of the trial.

A separate study published the same year found that metformin also blocked the mitochondrial adaptations that exercise normally produces. When healthy people train aerobically, their muscle mitochondria become more numerous and more efficient, and this is one of the key mechanisms by which exercise improves insulin sensitivity over time. In older adults taking metformin during training, those mitochondrial improvements were blunted. The exercise was still happening. The adaptation was not following.

That second finding matters because it closes a door you might have thought was still open. Even if someone on metformin is not trying to build larger muscles, they are still losing some of the metabolic benefit of the exercise they are doing, because the mitochondrial upgrade that would make their cells more insulin sensitive is being partially blocked by the same drug they are taking to manage insulin resistance.

Now here is where you can see the cycle clearly.

You lose muscle mass, or your existing muscle becomes insulin resistant. This impairs glucose clearance. You develop elevated blood sugar or type 2 diabetes. You are prescribed metformin. Metformin helps control the blood sugar numbers in the short term by activating AMPK. But AMPK suppresses mTOR, which means resistance training produces less muscle growth than it should. The exercise you are doing to build back the tissue that would fix the root problem is being partially undermined by the drug you are taking to manage the symptom of not having enough functional muscle tissue. And the underlying deficit stays in place.

None of this means metformin is always the wrong choice. There are situations where blood sugar control is urgent and the immediate risk of elevated glucose outweighs other considerations. That is a conversation between a patient and their physician who knows their full picture.

But what you should take away from this is the mechanism, because the mechanism tells you what the drug is actually doing and what it cannot do. Metformin manages a number on a lab result. Resistance training rebuilds the tissue that is responsible for the biology behind that number. The drug and the adaptation it partially blocks are working in opposite directions, and knowing that changes the conversation you can have about your care.

The goal was never a better number. The goal was muscle that clears glucose the way it was supposed to.

---

References

1. DeFronzo RA et al. (1981). "The effect of insulin on the disposal of intravenous glucose." J Clin Invest. 68(6):1468-1474. Finding: Skeletal muscle responsible for approximately 80% of insulin-mediated glucose disposal. PMID: 7033285
2. DeFronzo RA (2009). "From the triumvirate to the ominous octet." Banting Lecture. Diabetes Care. 32(Suppl 2):S157-S163. Finding: Muscle insulin resistance is a core defect in type 2 diabetes. PMID: 19875544
3. Walton RG et al. (2019). "Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: The MASTERS trial." Aging Cell. 18(6):e13039. Finding: n=94, adults 65+, placebo group gained significantly more muscle. PMID: 31557380
4. Konopka AR et al. (2019). "Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults." Aging Cell. 18(1):e12880. Finding: Metformin blocked exercise-induced mitochondrial improvements. PMID: 30548390
5. Drewe J et al. (2026). "Metformin: Mechanism of action." Pharmacol Rev. Finding: Complex I inhibition activates AMPK. PMID: 41389439
6. Inoki K et al. (2003). Nat Cell Biol. Finding: AMPK phosphorylates TSC2, suppressing mTOR. PMID: 12847286
7. Gwinn DM et al. (2008). Mol Cell. Finding: AMPK phosphorylates Raptor to suppress mTORC1. PMID: 18439900
8. Bolster DR et al. (2002). J Biol Chem. Finding: AMPK activation reduces muscle protein synthesis through mTOR suppression. PMID: 12351658

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness